Patients with IBS may have reduced CD3+ and CD4+ counts, which leads to immune function disorders, the release of injurious immune factors, cell damage, persistent inflammatory reactions, and consequent dysfunction of sensory, secretory, and motor functions of the gut.[44] Therefore, we speculate that CHM has the desired holistic and bidirectional immune regulatory functions in PCD. Here, CD4 is linked to irritable bowel syndrome.